Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIB) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 396,900 shares, a decline of 33.5% from the January 31st total of 596,800 shares. Based on an average trading volume of 2,090,000 shares, the short-interest ratio is currently 0.2 days. Approximately 3.6% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Trinity Biotech in a research note on Wednesday, February 26th. They set a “hold” rating on the stock.

Trinity Biotech Price Performance

Shares of Trinity Biotech stock traded down $0.04 during trading on Monday, hitting $0.70. 133,441 shares of the company’s stock traded hands, compared to its average volume of 3,262,295. Trinity Biotech has a 1 year low of $0.66 and a 1 year high of $3.55. The business has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $1.28. The stock has a market capitalization of $12.56 million, a P/E ratio of -0.31 and a beta of 1.03.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period. 78.97% of the stock is currently owned by institutional investors and hedge funds.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.